辰光医疗2025年三季报显示，前三季度公司主营收入6774.26万元，同比下降21.33%；归母净利 润-1933.07万元，同比下降21.77%；扣非净利润-2148.9万元，同比下降3.01%；其中2025年第三季度， 公司单季度主营收入2038.99万元，同比下降29.57%；单季度归母净利润-451.3万元，同比上升3.33%； 单季度扣非净利润-528.12万元，同比上升9.47%；负债率48.48%，投资收益23.9万元，财务费用385.49 万元，毛利率49.73%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，辰光医疗发布业绩预告，预计2025年全年归属净利润亏损5300万元至6600万元。 公告中解释本次业绩变动的原因为： 2025年度公司营业收入有所下降,公司营收增长仍受磁共振整机行业竞争格局影响。2025年中国磁共振 系统市场保持持续竞争态势,特别是头部企业针对集采"带量采购,以量换价"的政策,医学影像设备行业中 标价同比大幅下降,因此公司的1.5T磁共振系统销售收入受到影响。此外公司7.0T ...

证券代码：920300 证券简称：辰光医疗 公告编号：2026-012 上海辰光医疗科技股份有限公司 2025 年年度业绩预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 二、本期业绩重大变化的主要原因 2025 年度公司营业收入有所下降，公司营收增长仍受磁共振整机行业竞 争格局影响。2025 年中国磁共振系统市场保持持续竞争态势，特别是头部企业 针对集采"带量采购，以量换价"的政策，医学影像设备行业中标价同比大幅 下降，因此公司的 1.5T 磁共振系统销售收入受到影响。此外公司 7.0T 磁共振 系统，由于属于科研用小众产品、单价高，市场销售存在不稳定性，2025 年没 有实现销售，对公司营业收入产生较大影响。 三、风险提示 一、本期业绩预告情况 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 √年度净利润为负值 单位：万元 | 项目 | 本报告期 | 上年同期 | | 变动比例% | | --- | --- | --- | --- ...

Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

Group 1 - The report highlights the strategic support from the National Medical Insurance Administration for the "going out" strategy of Chinese pharmaceuticals and medical devices, indicating a systematic empowerment phase for international expansion [10][11][12] - By 2025, China is expected to approve 76 innovative drugs, with over 150 transactions for external authorization, amounting to more than 130 billion USD, showcasing the global appeal of Chinese pharmaceutical innovations [11][12] - The medical equipment export market is projected to cover over 190 countries and regions, with a global market share of 8.17% in 2024, ranking China fourth globally [21][31] Group 2 - The report notes that the revenue of medical device manufacturing companies in China is expected to reach 1.42 trillion CNY in 2025, reflecting a year-on-year growth of 5% [16][19] - As of October 2025, the number of medical device manufacturers in China is projected to reach 33,300, indicating a continuous increase in production capacity [19][20] - The number of effective invention patents in the medical device sector is expected to reach 50,525 in 2024, representing a year-on-year growth of 21.63%, which supports innovation in the industry [20][24] Group 3 - The report identifies eight medical device and biopharmaceutical companies listed on the Beijing Stock Exchange, including Danaher Biologics, Beikang, and others, highlighting their market presence [34][30] - Among the 101 companies listed on the New Third Board related to medical devices, 31 are recognized as national-level specialized and innovative "little giant" enterprises, with six expected to achieve a net profit exceeding 70 million CNY in 2024 [34][35] - The report mentions that 14 companies in the medical and biological field are currently awaiting approval on the Beijing Stock Exchange, with an average revenue of 438 million CNY in 2024 [48][51]

证券代码：920300 证券简称：辰光医疗 公告编号：2026-010 （一）会议召开情况 1.会议召开时间：2026 年 1 月 20 日 下午 15:00 2.会议召开地点：上海市青浦区华青路 1269 号 3.会议召开方式：本次会议采用现场投票和网络投票相结合方式召开 4.会议召集人：公司第五届董事会 5.会议主持人：董事长 王杰先生 上海辰光医疗科技股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）审议通过《关于公司拟向招商银行股份有限公司上海分行申请并使用授信 额度的议案》 1.议案表决结果： 6.召开情况合法合规的说明： 本次股东会会议召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。会议召开不需要相关部门批准或履行必要程序。 （二）会议出席情况 出席和授权出席本次股东会的股东共 6 人，持有表决权的股份总数 25,754,102 股，占公司有表决权股份总数的 30.0000%。 其中通过网 ...

之 法律意见书 上海市海华永泰律师事务所 关于上海辰光医疗科技股份有限公司 2026 年第一次临时股东会 上海总部：上海市浦东新区陆家嘴环路 1366 号富士康大厦 12 层 电话：8621—58773177 传真：8621—58773268 二零二六年一月 上海市海华永泰律师事务所 关于上海辰光医疗科技股份有限公司 2026年第一次临时股东会 之 法律意见书 致:上海辰光医疗科技股份有限公司 上海市海华永泰律师事务所（以下简称"本所"）接受上海辰光医疗科技股 份有限公司（以下简称"公司"）的委托，指派本所王依来律师（以下简称"经 办律师"）出席了公司 2026年第一次临时股东会会议（以下简称"本次股东会"), 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》(以下简称"《证券法》")、中国证券监督管理委员会发布的《上市 公司股东会规则》(以下简称"《股东会规则》")、《上海辰光医疗科技股份有 限公司章程》（以下简称"《公司章程》"）和《上海辰光医疗科技股份有限公 司股东会议事规则》（以下简称"《股东会议事规则》"）等规定,对本次股东 会的相关事宜依法见证，并出具本法律意见书 ...

证券代码：920300 证券简称：辰光医疗 公告编号：2026-009 上海辰光医疗科技股份有限公司 原保荐代表人韩佳先生因工作安排原因，不再负责公司持续督导工作。为保 证持续督导工作的有序进行，国泰海通现委派孟庆嵩先生（简历详见附件）接替 韩佳先生担任持续督导保荐代表人，继续履行持续督导职责。 本次保荐代表人的变更不影响国泰海通对公司的持续督导工作。变更后，国 泰海通负责公司持续督导工作的保荐代表人为孟庆嵩先生、王莉女士。 公司董事会对韩佳先生担任公司保荐代表人期间所做的工作表示衷心感谢！ 上海辰光医疗科技股份有限公司 董事会 2026 年 1 月 16 日 附件：孟庆嵩先生简历 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2026 年 1 月 16 日 收到国泰海通证券股份有限公司（以下简称"国泰海通"）出具的《国泰海通证 券股份有限公司关于更换上海辰光医疗科技股份有限公司持续督导保荐代表人 的函》。 国泰海通 ...

Core Viewpoint - Chuangguang Medical announced the completion of its fundraising project "Research and Custom Superconducting Magnet Development Project" by December 18, 2025, and the funds have been fully utilized as per regulations [2] Group 1 - The company has completed the construction of the fundraising project and it has reached the predetermined usable status [2] - The remaining balance of the fundraising account, amounting to 947,791.67 yuan (including interest income), has been transferred to the company's general bank account for working capital supplementation [2] - The special fundraising account was officially closed on January 14, 2026, to facilitate the management of the raised funds [2]

上海辰光医疗科技股份有限公司 证券代码：920300 证券简称：辰光医疗 公告编号：2026-008 关于注销部分募集资金专项账户的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 | 序 | 账户名称 | 银行名称 | 账号 | 募集资金专 | 账户状态 | | --- | --- | --- | --- | --- | --- | | 号 | | | | 户用途 | | | 1 | 上 海 辰 光 医 疗 科 技 | 中国建设银行股 份有限公司上海 | | 磁共振系统 集成研发产 | 正常使用 | | | 股 份 有 限 | 长三角一体化示 | 31050183360009998888 | 业化及营销 | | | | 公司 | 范区支行 | | 升级项目 | | | 2 | 上 海 辰 光 医 疗 科 技 | 招商银行股份有 限公司上海青浦 | 121914073010818 | 科研定制型 超导磁体研 | 本次注销 | | | 股 份 有 限 | | | | | | | 公司 | 支行 | | ...

Core Viewpoint - The quantum technology sector in the A-share market is experiencing a surge, driven by supportive policies from both central and local governments, marking a transition from research to industrialization [1][2][5] Group 1: Market Activity - Quantum technology concept stocks saw significant gains, with leading stock Keda Guochuang (300520) hitting a 20% increase, closing at 52.72 yuan per share [1] - Other stocks like Geer Software (603232) also reached their daily limit, indicating heightened market activity in the sector [1] Group 2: Policy Support - The Ministry of Industry and Information Technology emphasized accelerating the development of emerging industries during the 14th Five-Year Plan, focusing on quantum technology, humanoid robots, brain-computer interfaces, and more [1] - Local governments in cities like Beijing, Shanghai, and Shenzhen are implementing special policies, including setting up industrial funds and innovation platforms to enhance the sector's development [1][2] Group 3: Core Value of Quantum Technology - Quantum technology is seen as a cornerstone for new productive forces, with its core areas being quantum communication, quantum computing, and quantum sensing [2] - Quantum communication offers absolute security, making it crucial for sectors like finance and national defense, while quantum computing has the potential to revolutionize fields such as drug development and weather forecasting [2] Group 4: Market Growth Potential - The quantum technology market is expected to grow significantly, with predictions indicating a global market size exceeding $6.1 billion by 2025, and China's market reaching 11.56 billion yuan, with a compound annual growth rate of over 30% [3] Group 5: Company Developments - Companies are actively engaging in quantum technology, with firms like Qiming Star (002439) collaborating with China Mobile (600941) on quantum computing security, and Jiuzhiyang (300516) focusing on optical and quantum technology applications [4] - However, companies like Bichuang Technology (300667) have noted that their order sizes are currently small, indicating potential investment risks [4] Group 6: Investment Sentiment - The recent strength in the quantum technology sector is largely driven by policy catalysts, reflecting market expectations for cutting-edge technology [5] - Despite the long-term potential, most technologies are still in the research and early application stages, suggesting that investors should differentiate between long-term value and short-term speculative risks [5]